{"id":"NCT03547271","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","officialTitle":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-14","primaryCompletion":"2023-05-17","completion":"2023-05-24","firstPosted":"2018-06-06","resultsPosted":"2025-01-22","lastUpdate":"2025-03-03"},"enrollment":1660,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"MenACYW conjugate vaccine","otherNames":["MenQuadfi®"]},{"type":"BIOLOGICAL","name":"Meningococcal group A, C, W-135, and Y conjugate vaccine","otherNames":["Nimenrix®"]},{"type":"BIOLOGICAL","name":"DTaP-IPV-HB-Hib vaccine","otherNames":["Hexyon®/Hexacima®"]},{"type":"BIOLOGICAL","name":"Pneumococcal vaccine (13-valent)","otherNames":["Prevenar 13®"]},{"type":"BIOLOGICAL","name":"Pneumococcal vaccine (10-valent)","otherNames":["Synflorix®"]},{"type":"BIOLOGICAL","name":"MMR vaccine","otherNames":["M-M-RVAXPRO®"]}],"arms":[{"label":"Group 1: MenACYW","type":"EXPERIMENTAL"},{"label":"Group 2: Nimenrix","type":"ACTIVE_COMPARATOR"},{"label":"Group 3: MenACYW","type":"EXPERIMENTAL"},{"label":"Group 4: MenACYW","type":"EXPERIMENTAL"}],"summary":"Primary objective:\n\nThis study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b \\[DTaP-IPV-HB-Hib vaccine\\]) to infants and toddlers 6 weeks to 18 months old\n\nSecondary objectives:\n\nThis study aimed to demonstrate the non-inferiority of the antibody (Ab) response against meningococcal serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old.\n\n\\- This study aimed to describe the Ab responses against meningococcal groups A, C, Y, and W and the antigens of the routine pediatric vaccines administered in the study.","primaryOutcome":{"measure":"Groups 1 and 2: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y","timeFrame":"At 30 days post Dose 3 [12 to 18 months of age (MoA)]","effectByArm":[{"arm":"Group 1: MenACYW","deltaMin":131,"sd":null},{"arm":"Group 2: Nimenrix","deltaMin":189,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":33,"countries":["Czechia","Finland","Italy","Poland","Romania","Spain","Sweden"]},"refs":{"pmids":["40665158"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":696},"commonTop":["Irritability","Crying","Injection Site Pain","Somnolence","Injection Site Erythema"]}}